.Merck defeats profits desires, brings up sales outlook on powerful demand for best medicines like Keytruda CNBCMerck & Co. (MRK US) Trumps Income Forecasts as Keytruda Purchases Growth BloombergMerck Sell: Pharma Giant Posts Solid Results, Yet Outlook Falls Short Financier's Organization DailyMerck Announces Second-Quarter 2024 Financial Results Yahoo FinanceMerck trumps earnings as well as purchases requirements surrounded by Keytruda advantage, however gives combined full-year outlook MarketWatch.